This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-30813

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05904496
Recruitment Status : Recruiting
First Posted : June 15, 2023
Last Update Posted : October 27, 2023
Sponsor:
Information provided by (Responsible Party):
BeiGene

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy and in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: BGB-30813 Drug: Tislelizumab Phase 1

Detailed Description:

This study will test whether taking BGB-30813 alone or with tislelizumab can help treat patients with cancer that has spread throughout the body or is locally advanced. The two main goals of the study are to ensure that the treatments are safe by monitoring side effects and to determine the number of patients who respond well to treatment either partially or completely. The combination of BGB-30813 with other drugs that target immune checkpoints may work together to stop or prevent cancer activity.

Approximately 209 patients will participate. In the first part of the study, patients will be given different doses of BGB-30813 either alone or with tislelizumab to find the dose that is best tolerated. BGB-30813 will be given orally and tislelizumab will be given through a vein. In the second part of the study, the selected dose of BGB-30813, either alone or with tislelizumab, will be given to a larger number of patients from different parts of the world to see if the treatments can improve the signs and symptoms of their cancer. Treatments will continue until patients are no longer considered to be receiving benefits, have unacceptable side effects, or withdraw consent.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 209 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
Actual Study Start Date : July 19, 2023
Estimated Primary Completion Date : May 2025
Estimated Study Completion Date : May 2026
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Phase 1a: Dose Escalation Part A: BGB-30813 Monotherapy Drug: BGB-30813
Specified dose administered on specified days
Experimental: Phase 1a: Dose Escalation Part B: BGB-30813 + Tislelizumab Drug: BGB-30813
Specified dose administered on specified days

Drug: Tislelizumab
Specified dose administered on specified days
Other Name: BGB-A317
Experimental: Phase 1b: Dose Expansion BGB-30813 in Combination with Tislelizumab Drug: BGB-30813
Specified dose administered on specified days

Drug: Tislelizumab
Specified dose administered on specified days
Other Name: BGB-A317


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Phase 1a: Dose Escalation: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose-Limiting Toxicities (DLTs) [ Time Frame: Up to Approximately 23 months ]
  2. Phase 1a : Dose Escalation: The Maximum Tolerated Dose (MTD) and Maximum Administered Dose (MAD) and Recommended dose(s) for Expansion (RDFE[s]) of BGB-30813 Alone or in Combination with Tislelizumab [ Time Frame: Up to approximately 23 months ]

    The MTD or MAD is defined as the highest dose at which 30% of participants experience a DLT or the highest dose administered, respectively.

    The RDFE(s) of BGB-30813 alone or in combination with tislelizumab, determined based upon the MTD or MAD and other relevant data.


  3. Phase 1b: Dose Expansion: Overall Response Rate (ORR) as Determined by the Investigator [ Time Frame: Up to approximately 2 years and 11 months ]
    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as determined from tumor assessments by the investigator per RECIST version 1.1


Secondary Outcome Measures :
  1. Phase 1a: Dose Escalation: ORR as Determined by the Investigator [ Time Frame: Up to approximately 23 months ]
    ORR is defined as the percentage of participants who had confirmed CR or PR as determined from tumor assessments by the investigator per RECIST version 1.1

  2. Phase 1a: Maximum Observed Plasma Concentration (Cmax) Of BGB-30813 and Metabolite BGB-33481 Alone and in Combination with Tislelizumab [ Time Frame: From Cycle 1 Day 1 up to Cycle 9 Day 1 ]
  3. Phase 1a: Dose Escalation: Observed Plasma Trough Concentration (Ctrough) Of BGB-30813 and Metabolite BGB-33481 Alone and in Combination with Tislelizumab [ Time Frame: From Cycle 1 Day 1 up to Cycle 9 Day 1 ]
  4. Phase 1a: Dose Escalation: Area Under the concentration-time curve (AUC) Of BGB-30813 and Metabolite BGB-33481 Alone and in Combination with Tislelizumab [ Time Frame: From Cycle 1 Day 1 up to Cycle 9 Day 1 ]
  5. Phase 1a: Dose Escalation: Half-life (t1/2) Of BGB-30813 and Metabolite BGB-33481 Alone and in Combination with Tislelizumab [ Time Frame: From Cycle 1 Day 1 up to Cycle 9 Day 1 ]
  6. Phase 1b: Dose Expansion: Number of Participants Experiencing TEAEs, and SAEs [ Time Frame: Up to approximately 2 years and 11 months ]
  7. Phase 1b: Dose Expansion: Duration of Response (DOR) [ Time Frame: Up to approximately 2 years and 11 months ]
    DOR is defined as the time from the first determination of an overall response assessed by the investigator using RECIST v1.1, until the first documentation of disease progression or death, whichever comes first.

  8. Phase 1b: Dose Expansion: Disease Control Rate (DCR) [ Time Frame: Up to approximately 2 years and 11 months ]
    DCR is defined as the percentage of participants with best overall response (BOR) of complete Response (CR), Partial Response (PR), or stable disease assessed by the investigator using RECIST v1.1.

  9. Phase 1b: Dose Expansion: Progression Free Survival (PFS) [ Time Frame: Up to approximately 2 years and 11 months ]
    PFS is defined as the time from the date of the first dose of study drugs to the date of the first documentation of disease progression assessed by the investigator using RECIST v1.1 or death, whichever occurs first.

  10. Phase 1b: Dose Expansion: Clinical Benefit Rate (CBR) [ Time Frame: Up to approximately 2 years and 11 months ]
    CBR is defined as the percentage of participants with BOR of confirmed CR, PR, or stable disease lasting ≥ 24 weeks


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Phase 1a (Dose Escalation):

    • Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received available standard systemic therapy or for whom treatment is not available or not tolerated and who have not received any prior therapy targeting diacylglycerol kinase ζ (DGK)

      • Eligible tumor types are immune sensitive solid tumors such as NSCLC, HNSCC, small cell lung cancer, hepatocellular carcinoma, esophageal cancer, gastric or gastroesophageal carcinoma, nasopharyngeal carcinoma, triple-negative breast cancer, urothelial carcinoma, renal cell carcinoma, cervical cancer, endometrial carcinoma, cutaneous squamous cell carcinoma, melanoma, Merkel cell carcinoma, mesothelioma, microsatellite instability (MSI)-high, tumor mutation burden (TMB)-high, or mismatch repair deficient solid tumors
      • Prior checkpoint inhibitor (CPI) therapy is allowed

  • Phase 1b (Dose Expansion):

    • Participants with selected advanced or metastatic solid tumors including NSCLC, HNSCC, and additional potential tumor types to be defined based on emerging data
  • ≥ 1 measurable lesion per RECIST v1.1
  • Eastern Cooperative Group Oncology Performance (ECOG) Performance Status score ≤ 1
  • Females of childbearing potential must be willing to use a highly effective method of birth control for the duration of the study
  • Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: Hemoglobin≥ 90 grams per liter (g/L), Absolute neutrophil count ≥ 1.5 x 109/L , Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (< 3 x ULN for participants with Gilbert syndrome ), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN

Exclusion Criteria:

  • Previous therapy targeting DGK
  • Active leptomeningeal disease or uncontrolled symptomatic central nervous system (CNS) metastasis
  • Active autoimmune diseases or history of autoimmune diseases that may relapse
  • Any active malignancy ≤ 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
  • Systemic anticancer therapy, including chemotherapy ≤ 21 days or 5 half-lives (whichever is shorter) before the first dose of study drugs

Note: Other Criteria may apply

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05904496


Contacts
Layout table for location contacts
Contact: Study Director 1-877-828-5568 clinicaltrials@beigene.com

Locations
Layout table for location information
United States, Texas
Next Oncology Recruiting
San Antonio, Texas, United States, 78229
Australia, Victoria
Monash Health Recruiting
Clayton, Victoria, Australia, 3168
Peter Maccallum Cancer Centre Recruiting
Melbourne, Victoria, Australia, 3000
Australia, Western Australia
Linear Clinical Research Recruiting
Nedlands, Western Australia, Australia, 6009
Spain
Hospital Universitario Vall Dhebron Recruiting
Barcelona, Spain, 08035
Start Madrid Fundacion Jimenez Diaz Recruiting
Madrid, Spain, 28040
Sponsors and Collaborators
BeiGene
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT05904496    
Other Study ID Numbers: BGB-A317-30813-101
U1111-1290-6118 ( Other Identifier: WHO )
2023-503996-38 ( EudraCT Number )
First Posted: June 15, 2023    Key Record Dates
Last Update Posted: October 27, 2023
Last Verified: October 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by BeiGene:
DGKζ Inhibitor
BGB-30813
Anti-PD-1 Monoclonal Antibody
Tislelizumab
Advanced or Metastatic Solid Tumors
 Diacylglycerol kinase
BGB-A317
NSCLC
Immunotherapy
HNSCC
Additional relevant MeSH terms:
Layout table for MeSH terms
Tislelizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents